Treatment of Irq-Un-Nisa (Sciatica) with Unani medicine Habb-e-Irq-un-Nisa

An Open-Label, Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial Formulations â?? Habb-e-Irq-un-Nisa in Irq-Un-Nisa (Sciatica)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/01/039133

Enrollment

110

Registered

2022-01-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M543- Sciatica

Interventions

Intervention1: Habb-e-Irq-un-Nisa: 1tablet (400mg) Orally twice daily to be taken with lukewarm water after meals for 8 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of either sex in the age group of 18 to 65 years. 2. Typical radiating pain from lumbar to buttock to back of the leg 3. Pain exacerbated by coughing, sneezing or bending. 4. Subjects with positive straight Leg Raise (SLR) test 5.Presence of following symptoms indicating Sciatica. Unilateral leg pain greater than low back pain Pain radiating to foot and toes numbness and paraesthesia

Exclusion criteria

Exclusion criteria: 1. Known case of any systemic illness, uncontrolled DM, uncontrolled Hypertension, Hepatic, Renal or Cardiac ailments TB, CNS involvement, HIV infection. 2. Known case of Herniated lumbo-sacral disc 3. Known case of Nerve root impingement (herniated disc, bulging disc, trauma or injury, such as from a fall,spinal stenosis, mechanical stretching,bone spur formation,spondylolisthesis,foraminal stenosis,degeneration,rheumatoid arthritis) 4. Known case of Epidural abscess and Epidural hematoma 5. Known case of Spinal Tumor 6. Known case of Potts Disease, also known as spinal tuberculosis 7. Known case of Piriformis syndrome 8. Obese subjects (BMI >=30) 9. H/O Addictions (Alcohol, drugs) 10. Pregnant and lactating women 11. History of hypersensitivity to study drug or any of its ingredients

Design outcomes

Primary

Measure	Time frame
Improvement in sign and symptoms of Irq-Un-Nisa (Sciatica)Timepoint: At baseline, 2, 4, 6 and 8 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessment Timepoint: At baseline and 8 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026